Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development.

Polasek TM, Rayner CR, Peck RW, Rowland A, Kimko H, Rostami-Hodjegan A.

Clin Pharmacol Drug Dev. 2019 May;8(4):418-425. doi: 10.1002/cpdd.638. Epub 2018 Nov 30.

PMID:
30500115
2.

Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study.

Kinrade SA, Mason JW, Sanabria CR, Rayner CR, Bullock JM, Stanworth SH, Sullivan MT.

Clin Transl Sci. 2018 Nov;11(6):582-589. doi: 10.1111/cts.12583. Epub 2018 Sep 19.

3.

Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.

Wu DBC, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Smith PF, Kirkpatrick CM, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Rayner CR.

Epidemiol Infect. 2018 Mar;146(4):496-507. doi: 10.1017/S0950268818000158. Epub 2018 Feb 15.

PMID:
29446343
4.

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.

Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Kirkpatrick CM, Rayner CR.

Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594. doi: 10.1111/bcp.13229. Epub 2017 Feb 20.

5.

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Oliver A, Tsuji BT, Rayner CR, Nation RL, Landersdorfer CB.

J Antimicrob Chemother. 2016 Nov;71(11):3157-3167. Epub 2016 Aug 11.

6.

Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.

Kamal MA, Brennan BJ, Subramoney V, Lien YT, Morcos PN, Frey N, Rayner CR.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):326-36. doi: 10.1002/cpdd.203. Epub 2015 Jul 2.

PMID:
27137141
7.

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.

Kamal MA, Gieschke R, Lemenuel-Diot A, Beauchemin CA, Smith PF, Rayner CR.

Antimicrob Agents Chemother. 2016 Feb 26;60(3):1953. doi: 10.1128/AAC.00179-16. Print 2016 Mar. No abstract available.

8.

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.

Reddy MB, Yang KH, Rao G, Rayner CR, Nie J, Pamulapati C, Marathe BM, Forrest A, Govorkova EA.

PLoS One. 2015 Oct 13;10(10):e0138069. doi: 10.1371/journal.pone.0138069. eCollection 2015.

9.

Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.

Kamal MA, Lien KY, Robson R, Subramoney V, Clinch B, Rayner CR, Gibiansky L.

Antimicrob Agents Chemother. 2015 Nov;59(11):6774-81. doi: 10.1128/AAC.01024-15. Epub 2015 Aug 17.

10.

A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression.

Kamal MA, Gieschke R, Lemenuel-Diot A, Beauchemin CA, Smith PF, Rayner CR.

Antimicrob Agents Chemother. 2015 Sep;59(9):5388-95. doi: 10.1128/AAC.00069-15. Epub 2015 Jun 22. Erratum in: Antimicrob Agents Chemother. 2016 Mar;60(3):1953.

11.

Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multicentre clinical trial.

Rath BA, Brzostek J, Guillén S, Niranjan V, Chappey C, Rayner CR, Clinch B.

Antivir Ther. 2015;20(8):815-25. doi: 10.3851/IMP2967. Epub 2015 May 27.

PMID:
26015411
12.

Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.

Gibiansky L, Giraudon M, Rayner CR, Brennan BJ, Subramoney V, Robson R, Kamal MA.

J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):225-36. doi: 10.1007/s10928-015-9411-7. Epub 2015 Mar 29.

PMID:
25821064
13.

Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis.

Patel K, Rayner CR, Giraudon M, Kamal MA, Morcos PN, Robson R, Kirkpatrick CM.

Br J Clin Pharmacol. 2015 Apr;79(4):624-35. doi: 10.1111/bcp.12526.

14.

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.

Kamal MA, Acosta EP, Kimberlin DW, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sánchez PJ, Ampofo K, Whitley R, Rayner CR.

Clin Pharmacol Ther. 2014 Sep;96(3):380-9. doi: 10.1038/clpt.2014.120. Epub 2014 May 27.

PMID:
24865390
15.

Clinical population pharmacokinetics and toxicodynamics of linezolid.

Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2014;58(4):2334-43. doi: 10.1128/AAC.01885-13. Epub 2014 Feb 10.

16.

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.

Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3478-87. doi: 10.1128/AAC.02440-12. Epub 2013 May 13.

17.

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3470-7. doi: 10.1128/AAC.02438-12. Epub 2013 May 13.

18.

Assessing mathematical models of influenza infections using features of the immune response.

Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CA.

PLoS One. 2013;8(2):e57088. doi: 10.1371/journal.pone.0057088. Epub 2013 Feb 28.

19.

Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.

Toovey S, Prinssen EP, Rayner CR, Thakrar BT, Dutkowski R, Koerner A, Chu T, Sirzen-Zelenskaya A, Britschgi M, Bansod S, Donner B.

Adv Ther. 2012 Oct;29(10):826-48. doi: 10.1007/s12325-012-0050-8. Epub 2012 Oct 2. Review.

PMID:
23054689
20.

Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.

Brennan BJ, Davies B, Cirrincione-Dall G, Morcos PN, Beryozkina A, Chappey C, Aceves Baldó P, Lennon-Chrimes S, Rayner CR.

Antimicrob Agents Chemother. 2012 Sep;56(9):4729-37. doi: 10.1128/AAC.00200-12. Epub 2012 Jun 25.

21.

Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.

Poirier A, Belli S, Funk C, Otteneder MB, Portmann R, Heinig K, Prinssen E, Lazic SE, Rayner CR, Hoffmann G, Singer T, Smith DE, Schuler F.

Drug Metab Dispos. 2012 Aug;40(8):1556-65. doi: 10.1124/dmd.112.044990. Epub 2012 May 14.

22.

Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R.

Adv Ther. 2011 Nov;28(11):927-59. doi: 10.1007/s12325-011-0072-7. Epub 2011 Nov 1. Review.

PMID:
22057727
23.

Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.

Uchimura N, Kuwahara H, Kumagai Y, Mishima K, Inoue Y, Rayner CR, Toovey S, Davies BE, Hosaka Y, Abe M, Prinssen EP.

Basic Clin Pharmacol Toxicol. 2011 Oct;109(4):309-14. doi: 10.1111/j.1742-7843.2011.00726.x. Epub 2011 Jun 29.

24.

A new approach to teaching undergraduates about occupational health issues.

Rayner CR, Burns P.

Educ Prim Care. 2011 Mar;22(2):109-12. No abstract available.

PMID:
21439143
25.

Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL.

Antimicrob Agents Chemother. 2010 Mar;54(3):1117-24. doi: 10.1128/AAC.01114-09. Epub 2009 Dec 22.

26.

Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.

Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR, Chu T, Prinssen EP.

Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61. doi: 10.1128/AAC.01541-08. Epub 2009 Aug 31.

27.

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93. doi: 10.1128/AAC.00327-08. Epub 2008 Aug 1.

28.

Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL.

Antimicrob Agents Chemother. 2008 Sep;52(9):3047-51. doi: 10.1128/AAC.00103-08. Epub 2008 Jul 7.

29.

Population pharmacokinetics of oseltamivir when coadministered with probenecid.

Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN.

J Clin Pharmacol. 2008 Aug;48(8):935-47. doi: 10.1177/0091270008320317. Epub 2008 Jun 4.

PMID:
18524996
30.

Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens.

Wallace SJ, Li J, Nation RL, Rayner CR, Taylor D, Middleton D, Milne RW, Coulthard K, Turnidge JD.

Antimicrob Agents Chemother. 2008 Mar;52(3):1159-61. doi: 10.1128/AAC.01101-07. Epub 2008 Jan 7.

31.

Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.

Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL.

Br J Clin Pharmacol. 2008 May;65(5):667-73. Epub 2007 Dec 17.

32.

Comments on "Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel".

Fowler S, Lennon SM, Hoffmann G, Rayner CR.

J Pharmacol Exp Ther. 2007 Jul;322(1):422-3; author reply 424-5. No abstract available.

PMID:
17578904
33.

Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.

Schentag JJ, Hill G, Chu T, Rayner CR.

J Clin Pharmacol. 2007 Jun;47(6):689-96. Epub 2007 Apr 24.

PMID:
17456583
34.

Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Boak LM, Li J, Rayner CR, Nation RL.

Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. Epub 2007 Jan 22.

35.

Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.

Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL.

Br J Clin Pharmacol. 2007 Mar;63(3):315-21. Epub 2006 Sep 19.

36.

Pharmacokinetics of oseltamivir in young and very elderly subjects.

Abe M, Smith J, Urae A, Barrett J, Kinoshita H, Rayner CR.

Ann Pharmacother. 2006 Oct;40(10):1724-30. Epub 2006 Aug 29.

PMID:
16940405
37.

Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L.

Antimicrob Agents Chemother. 2006 Sep;50(9):2946-50.

38.

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL.

Lancet Infect Dis. 2006 Sep;6(9):589-601. Review.

PMID:
16931410
39.

Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis.

Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1451-5. Epub 2006 Jun 13.

PMID:
16772405
40.

Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Bergen PJ, Li J, Rayner CR, Nation RL.

Antimicrob Agents Chemother. 2006 Jun;50(6):1953-8.

41.

Colistin-associated acute renal failure: revisited.

Li J, Rayner CR, Nation RL.

South Med J. 2005 Dec;98(12):1229-30. No abstract available.

PMID:
16440932
42.

High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma.

Boak LM, Li J, Nation RL, Rayner CR.

Biomed Chromatogr. 2006 Aug;20(8):782-6.

PMID:
16292746
43.

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, Douglas A, Lipman J.

Antimicrob Agents Chemother. 2005 Nov;49(11):4814-5. No abstract available.

44.

Differential bidirectional transfer of indinavir in the isolated perfused human placenta.

Sudhakaran S, Ghabrial H, Nation RL, Kong DC, Gude NM, Angus PW, Rayner CR.

Antimicrob Agents Chemother. 2005 Mar;49(3):1023-8.

45.

Multidisciplinary HIV adherence intervention: a randomized study.

Levy RW, Rayner CR, Fairley CK, Kong DC, Mijch A, Costello K, McArthur C; Melbourne Adherence Group.

AIDS Patient Care STDS. 2004 Dec;18(12):728-35.

PMID:
15659884
46.

Simple method for the assay of eperezolid in brain heart infusion broth by high-performance liquid chromatography.

Li J, Rayner CR, Nation RL.

J Pharm Biomed Anal. 2004 Jun 29;35(4):847-51.

PMID:
15193729
47.

Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ.

Infection. 2004 Feb;32(1):8-14.

PMID:
15007736
48.

Simple method for the assay of linezolid in Brain Heart Infusion broth by high-performance liquid chromatography.

Li J, Rayner CR, Dixson S, Nation RL.

Biomed Chromatogr. 2004 Jan;18(1):1-5.

PMID:
14872541
49.

Randomized trial of an adherence programme for clients with HIV.

Fairley CK, Levy R, Rayner CR, Allardice K, Costello K, Thomas C, McArthur C, Kong D, Mijch A, Melbourne Adherence Group; Melbourne Adherence Group.

Int J STD AIDS. 2003 Dec;14(12):805-9.

PMID:
14678587
50.

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ.

Clin Pharmacokinet. 2003;42(15):1411-23.

PMID:
14674791

Supplemental Content

Loading ...
Support Center